UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000046093
Receipt number R000052612
Scientific Title Double blind study of furosemide for Acute Kidney Injury(AKI)
Date of disclosure of the study information 2021/12/01
Last modified on 2021/11/17 11:19:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Double blind study of furosemide for Acute Kidney Injury(AKI)

Acronym

Furosemide for AKI

Scientific Title

Double blind study of furosemide for Acute Kidney Injury(AKI)

Scientific Title:Acronym

Furosemide for AKI

Region

Japan


Condition

Condition

Acute Kidney Injury

Classification by specialty

Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Effect of furosemide for Acute Kidney Injury

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Renal function for 30 days since Acute Kidney Injury was recognized

Key secondary outcomes

Duration of ICU stay, Duration of hospital stay, usage of RRT


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Normal saline 0.2ml/kg/h for placebo group will be administered for first 6 hours since AKI is recognized. When urine amount is gained over 3ml/kg/h, the drug is reduced by 0.05ml/kg/h with every 2 hours. When urine amount is not over 1ml/kg/h for 6 hours after the drug administration is started, Furosemide (2mg/ml) is administered with 0.2ml/kg/h for both groups and ordinal intervention is started. As any time rule to prevent dehydration, when urine amount is over 3ml/kg, linger solution administration is started with 0.5ml x urine amount (ml/h). CRTN level and urine amount is evaluated everyday for first 10 days and furosemide administration is continued until CRTN level change is under 0.05mg/dl. CRRT intervention is allowed as needed. Duration of observation is first 10 days since started and 30 days later.

Interventions/Control_2

Furosemide (2mg/ml) as 0.2ml/kg/h for AKI group will be administered for first 6 hours since AKI is recognized. When urine amount is gained over 3ml/kg/h, the drug is reduced by 0.05ml/kg/h with every 2 hours. When urine amount is not over 1ml/kg/h for 6 hours after drug administration is started, Furosemide (2mg/ml) is administered with 0.2ml/kg/h for both groups and ordinal intervention is started. As any time rule to prevent dehydration, when urine amount is over 3ml/kg, linger solution administration is started with 0.5ml x urine amount (ml/h). CRTN level and urine amount is evaluated everyday for first 10 days and furosemide administration is continued until CRTN level change is under 0.05mg/dl. CRRT intervention is allowed as needed. Duration of observation is first 10 days since started and 30 days later.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

ICU patients and KDIGO AKI score more than one

Key exclusion criteria

Patients on hemodiafiltration

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Masao
Middle name
Last name Hayashi

Organization

Kawasaki medical school general medical center

Division name

Anesthesiology and Intensive care medicine 3

Zip code

700-8505

Address

2-6-1 Nakasange Kita-ku, Okayama

TEL

086-225-2111

Email

mao893@aol.com


Public contact

Name of contact person

1st name Masao
Middle name
Last name Hayashi

Organization

Kawasaki medical school general medical center

Division name

Anesthesiology and Intensive care medicine 3

Zip code

700-8505

Address

2-6-1 Nakasange Kita-ku, Okayama

TEL

086-225-2111

Homepage URL


Email

mao893@aol.com


Sponsor or person

Institute

Kawasaki medical school general medical center

Institute

Department

Personal name



Funding Source

Organization

Kawasaki medical school general medical center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kawasaki medical school internal review board

Address

577 Matsushima Kurashiki, Okayama

Tel

086-464-1076

Email

kmsrec@med.kawasaki-m.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2021 Year 10 Month 25 Day

Date of IRB


Anticipated trial start date

2021 Year 12 Month 01 Day

Last follow-up date

2022 Year 12 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 11 Month 17 Day

Last modified on

2021 Year 11 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052612


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name